Download guide

This week's Fierce Biotech is brought to you by Sciensus.

Trouble viewing? Click here.
Sciensus
Unlock the EU rare disease market with post-authorization safety studies
Post-authorization safety studies (PASS) are often seen simply as regulatory obligations. But for biotech companies developing rare disease therapies, PASS offers a powerful strategic advantage far beyond safety monitoring alone.
In this exclusive guide, we cover:
• Navigating regulatory requirements while leveraging PASS for long-term success
• The pivotal role PASS plays in rare diseases, where patient data is limited
• Best practices for designing and executing an effective PASS
• How digital innovations are shaping the future of PASS
Download this guide to discover how to turn PASS into a key component of your strategy and drive sustainable growth for your rare disease therapies.
Download guide
linkedin

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.


You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017